Regencell Bioscience Limited (RGC), a Hong Kong-based developer of herbal treatments for ADHD and autism, saw its shares soar 6.35% in after-hours trading on Monday. This surge comes on the heels of an already remarkable year for the company, which has seen its stock price skyrocket by nearly 17,600% year-to-date.

The after-hours rally continues a pattern of extreme volatility for Regencell, which has puzzled market observers given the company's financial performance. Despite the stock's meteoric rise, Regencell has reported six consecutive years of net losses, including a $1.9 million loss for the six months ending December 31, 2024. This disconnect between stock performance and fundamentals has raised eyebrows among investors and analysts alike.

In its recent interim financial results, Regencell suggested that a "short squeeze" might be behind the extreme price volatility. However, experts have cast doubt on this explanation. Ihor Dusaniwsky, managing director of predictive analytics at S3 Partners, pointed out that Regencell's current short interest is only about 3% of its already limited float, making it unlikely that short sellers could significantly influence the share price. Instead, Dusaniwsky suggested that "long buying and long selling was by far the primary driver of its price moves." As Regencell continues to capture headlines with its volatile stock movements, investors are advised to approach with caution and conduct thorough due diligence.